两名 COVID-19 患者在抗病毒治疗期间发生 QTc 延长。
QTc prolongation during antiviral therapy in two COVID-19 patients.
机构信息
Department of Pharmacy, Ningbo First Hospital, Ningbo, China.
Department of Cardiology, Ningbo First Hospital, Ningbo, China.
出版信息
J Clin Pharm Ther. 2020 Oct;45(5):1190-1193. doi: 10.1111/jcpt.13183. Epub 2020 Jul 21.
WHAT IS KNOWN AND OBJECTIVE
Acquired long QT syndrome secondary to drug-induced QT prolongation and torsades de pointes has been reported for antiviral drugs. However, no studies have reported an association between corrected QT (QTc) prolongation and antiviral therapy in patients with novel coronavirus disease (COVID-19).
CASE DESCRIPTION
We present two cases from our institution in which patients with COVID-19 experienced QTc prolongation during treatment with antiviral therapy. Lopinavir/ritonavir, together with gender and drug-drug interactions, may have contributed to the induction of QTc prolongation in those patients.
WHAT IS NEW AND CONCLUSION
Co-administration of QT-prolonging medications and drugs interfering with the metabolism of those medications must be considered in patients with COVID-19. Careful analysis of electrocardiograms for QTc duration should be performed at baseline and during antiviral therapy to identify individuals at high risk of arrhythmias.
已知和目的
已有报道称，抗病毒药物可引起药物诱导的 QT 间期延长和尖端扭转型室速导致获得性长 QT 综合征。然而，尚无研究报告新型冠状病毒病（COVID-19）患者的 QT 间期校正（QTc）延长与抗病毒治疗之间的关联。
病例描述
我们报告了来自本机构的两例 COVID-19 患者，他们在接受抗病毒治疗期间出现 QTc 延长。洛匹那韦/利托那韦，加上性别和药物相互作用，可能导致了这些患者的 QTc 延长。
新内容和结论
必须考虑 COVID-19 患者同时使用 QT 延长药物和干扰这些药物代谢的药物。应在基线和抗病毒治疗期间仔细分析心电图 QTc 持续时间，以识别心律失常风险较高的个体。
Zotero 插件